Aurobindo P Expands US Presence with $15.25 Mil Acquisition

Aurobindo Pharma has completed the acquisition of A1 Biochem Labs LLC, a US-based contract research and chemistry services company, through its wholly owned subsidiary A1 USA Inc. The transaction was completed for a cash consideration of approximately $15.25 million. A1 Biochem Labs, based in Wilmington, North Carolina, provides contract research and chemistry services to pharmaceutical and biotechnology companies. The company reported sales of $9.23 million in 2024 and $5.92 million in 2025. Aurobindo Pharma said the acquisition is aligned with its strategy to strengthen its presence in the Active Pharmaceutical Ingredients business and build a Contract Research, Development and Manufacturing Organisation platform. The deal gives Aurobindo an opportunity to expand its capabilities in research and development as well as strengthen its US-based operations. The acquisition was completed on October 2, making it a fresh corporate development for the upcoming market session. Disclaimer: The views expressed purely for educational and informational purposes and do not constitute financial advice or a recommendation to buy, sell, or hold any security.